PREDICT v3.0 outperforms v2.2 in young (25-40 years) breast cancer patients according to real-world data from a large Swedish population-based registry
{{output}}
Background: PREDICT is a widely used prognostic tool supporting treatment decisions in breast cancer care. As v3.0 was recently released, we performed an external validation of PREDICT v2.2 and v3.0 in young (≤ 40 years) breast ... ...
